Abstract 1679, under the session ‘Drug Combination Strategies for Cancer Treatment’, showed that APG-2449, a novel focal ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...

Chronic pain, a common and debilitating condition, often leads practitioners to prescribe opioids in escalating doses.

China’s National Medical Products Administration (NMPA) has approved InnoCare Pharma’s Bruton's tyrosine kinase (BTK) ...

Recent research sheds light on how changes in the chemical structure of a protein called Interleukin-6 affect lung cancer’s ...

The ultimate goal of therapy for most patients will be TFR, and since this will, in many cases, be a key determinant of drug selection, it is preferable that this is discussed with the patient in ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...